Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
JMP Securities Reiterates Market Outperform Rating on Marinus Pharmaceuticals (MRNS)
August 13, 2024 4:09 PM EDTJMP Securities analyst Jason N. Butler reiterated a Market Outperform rating and $10.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS).
The analyst comments "Solid ZTALMY growth as we look to key Phase 3 TSC results by mid-4Q24; we reiterate our Market Outperform rating and $10 risk-adjusted,... More
Truist Securities Reiterates Buy Rating on Marinus Pharmaceuticals (MRNS)
August 13, 2024 4:04 PM EDTTruist Securities analyst Joon Lee reiterated a Buy rating and $10.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS).
The analyst comments "2Q24: Ph3 TrustTSC trial remain on track for topline in late Oct/early Nov. Low discontinuation rate of... More
